Anthelmintic avermectins kill mycobacterium tuberculosis, including multidrug-resistant clinical strains

118Citations
Citations of this article
139Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Avermectins are a family of macrolides known for their anthelmintic activities and traditionally believed to be inactive against all bacteria. Here we report that members of the family, ivermectin, selamectin, and moxidectin, are bactericidal against mycobacterial species, including multidrug-resistant and extensively drug-resistant clinical strains of Mycobacterium tuberculosis. Avermectins are approved for clinical and veterinary uses and have documented pharmacokinetic and safety profiles. We suggest that avermectins could be repurposed for tuberculosis treatment. Copyright © 2013, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Lim, L. E., Vilchèze, C., Ng, C., Jacobs, W. R., Ramón-García, S., & Thompson, C. J. (2013). Anthelmintic avermectins kill mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrobial Agents and Chemotherapy, 57(2), 1040–1046. https://doi.org/10.1128/AAC.01696-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free